Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 14/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978128 | 0.91 | DGAT1 (0.46) | LMNATP53MAPTCCR3KDM4E | |
| SCHEMBL4980033 | 0.89 | MAPT (0.48) | TP53MAPTCCR3KMT2AKDM4E | |
| SCHEMBL4974618 | 0.89 | HSP90AB1 (0.43) | LMNATP53MAPTKDM4EALDH1A1 | |
| SCHEMBL4976253 | 0.89 | KDM4E (0.48) | LMNAMAPTCCR3MEN1KMT2A | |
| SCHEMBL4978643 | 0.89 | ACHE (0.49) | LMNAMAPTMEN1KMT2AKDM4E | |
| SCHEMBL4980274 | 0.88 | TLR4 (0.39) | LMNATP53MAPTMEN1KMT2A | |
| SCHEMBL4976925 | 0.88 | LMNA (0.51) | LMNAMAPTCCR3MEN1KMT2A | |
| SCHEMBL4974974 | 0.88 | KDM4E (0.42) | LMNATP53MAPTKDM4EALDH1A1 | |
| SCHEMBL4976061 | 0.87 | KDM4E (0.57) | MAPTKDM4EALDH1A1 | |
| SCHEMBL4977153 | 0.87 | RBP4 (0.48) | MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | LMNA 4534/4885TP53 1765/4885MAPT 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.